A Mechanistic Evaluation of the Effects of Astragaloside IV 
on Neurite Outgrowth Under Oxygen-Glucose Deprivation 
Conditions

Hongxia Gan; Jiali Peng; Anni Qian; Xiaoyong Huang; Youming Fan*

doi:10.70711/pmr.v2i4.6110

A Mechanistic Evaluation of the Effects of Astragaloside IV on Neurite Outgrowth Under Oxygen-Glucose Deprivation Conditions

Hongxia Gan, Jiali Peng, Anni Qian, Xiaoyong Huang, Youming Fan*

Abstract

This study examined the effects of Astragaloside IV (AS-IV) on neurite outgrowth in PC12 cells subjected to oxygen-glucose deprivation (OGD). Cell viability assays demonstrated that increased OGD duration led to reduced cell viability, neurite length, and branching. ASIV treatment (20, 40, 80, and 160 g/ml) reversed these effects, enhancing cell activity and promoting longer neurites. Immunohistochemistry
showed elevated RhoA expression and decreased levels of growth-promoting proteins Rac1 and Cdc42 following OGD, but AS-IV treatment
lowered RhoA and increased Rac1 and Cdc42 levels. Additionally, pull-down assays indicated that AS-IV mitigated the activation of RhoA
while enhancing Rac1 and Cdc42, thus supporting neurite outgrowth by preventing collapse and promoting growth cone expansion.

Keywords

Ischemic stroke; Neurite regeneration; RhoA; Rac1; Cdc42; PC12 cells

Full Text:

PDF

Included Database

References

[1] Lee M C, Ting K K, Adams S, et al. Characterisation of the expression of NMDA receptors in human astrocytes[J]. PLoS One, 2010,

5(11): e14123.

[2] Fang Y, Iu C Y, Lui C N, et al. Investigating dynamic structural and mechanical changes of neuroblastoma cells associated with glutamate-mediated neurodegeneration[J]. Sci Rep, 2014, 4: 7074.

[3] Tedeschi A, Bradke F. Spatial and temporal arrangement of neuronal intrinsic and extrinsic mechanisms controlling axon regeneration[J].

Curr Opin Neurobiol, 2017, 42: 118-127.

[4] Macrez R, Stys P K, Vivien D, et al. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities[J].

Lancet Neurol, 2016, 15(10): 1089-1102.

[5] Wang X, Wang Y, Hu J P, et al. Astragaloside IV, a natural PPARgamma agonist, reduces Abeta production in Alzheimers disease

through inhibition of BACE1[J]. Mol Neurobiol, 2017, 54(4): 2939-2949.

[6] Wang Y, Zhou J, Tang C, et al. Positive effect of Astragaloside IV on neurite outgrowth via talin-dependent integrin signaling and microfilament force[J]. J Cell Physiol, 2021, 236(3): 2156-2168.

[7] CHEN B, YI J, XU Y, et al. Construction of a circRNA-miRNA-mRNA network revealed the potential mechanism of Buyang Huanwu

Decoction in the treatment of cerebral ischemia[J]. Biomed Pharmacother, 2022, 145(112445).

[8] Das J, G K R. Post stroke depression: The sequelae of cerebral stroke[J]. Neurosci Biobehav Rev, 2018, 90: 104-114.

[9] YANG J, LI J, LU J, et al. Synergistic protective effect of astragaloside IV-tetramethylpyrazine against cerebral ischemic-reperfusion

injury induced by transient focal ischemia[J]. J Ethnopharmacol, 2012, 140(1): 64-72.

[10] Hu J, Selzer M E. RhoA as a target to promote neuronal survival and axon regeneration[J]. Neural Regen Res, 2017, 12(4): 525-528.

DOI: http://dx.doi.org/10.70711/pmr.v2i4.6110

Refbacks

There are currently no refbacks.